Prestige Consumer Healthcare Inc.
PBHPrestige Consumer Healthcare Inc. is a consumer health company specializing in over-the-counter healthcare products, including pain relief, digestive health, and personal care items. It develops, manufactures, and markets a diverse portfolio of well-known brands, primarily serving North American and international markets. The company focuses on providing trusted, everyday healthcare solutions to consumers.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 15, 2014 | $0.31 | 2013-12-27 | 2013-12-31 |
Dividends Summary
- Consistent Payer: Prestige Consumer Healthcare Inc. has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held PBH shares during this period received a total of $0.31 per share in dividend income.
- Latest Payout: The most recent dividend of $0.31/share was paid 4567 days ago, on January 15, 2014.
Company News
Prestige Consumer Healthcare completed its acquisition of LaCorium Health for approximately $150 million on July 1, 2026. The company also priced a $400 million offering of 6.25% senior notes due 2034, with proceeds intended to redeem $400 million of existing 5.125% senior notes due January 2028. LaCorium, an Australian therapeutic skincare compa...
While Alphabet's addition to the Dow and prominence in Berkshire Hathaway's portfolio has garnered significant attention, Prestige Consumer Healthcare may offer better investment potential. Prestige completed its largest acquisition, purchasing Breathe Right and other OTC brands for $1.045 billion, expanding its portfolio of category-leading bran...
Prestige Consumer Healthcare (PBH) shares dropped over 11% on May 14, 2026, after the company reported significant revenue declines and production problems at its recently acquired Pillar5 facility. The facility, which was supposed to resolve Clear Eyes supply chain constraints, failed to deliver expected results. Q4 2026 revenues fell 5% year-ov...
Pomerantz LLP is investigating potential securities fraud claims against Prestige Consumer Healthcare Inc. following the company's May 13, 2026 earnings announcement that revealed a 4.5% organic revenue decline and production issues with Clear Eyes products. The stock fell 11.35% to $45.93 per share on May 14, 2026, prompting the investigation in...
The National Advertising Division reviewed advertising claims for eosera Inc.'s Ear Wax MD product in a challenge brought by Prestige Consumer Healthcare Inc. (marketer of Debrox). NAD found some establishment and mechanism-of-action claims were supported, but recommended discontinuing or modifying comparative superiority claims and unqualified e...
